Literature DB >> 7694682

Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V.

B Kehrel1, A Kronenberg, J Rauterberg, D Niesing-Bresch, U Niehues, J Kardoeus, B Schwippert, D Tschöpe, J van de Loo, K J Clemetson.   

Abstract

The aggregation of platelets induced by collagens is considered an important step in primary hemostasis. Glycoprotein (GP) IIIb (GPIIIb, GPIV, CD36) has been proposed as a blood platelet receptor for collagen. Platelets from three healthy blood donors were shown to be clearly deficient in GPIIIb. These platelets aggregated normally in response to type I and III collagens. In addition, platelet factor 4, beta-thromboglobulin, and adenosine triphosphate (ATP) secretion in response to type I and III collagens was normal. The findings indicate that GPIIIb is not the major, essential collagen receptor for type I and III collagens. This would explain why all individuals with GPIIIb-deficient platelets examined so far are healthy and, in particular, show no apparent evidence of hemostatic problems. However, in contrast to control platelets, no aggregation and impaired platelet factor 4, beta-thromboglobulin, and ATP secretion was observed in response to type V collagen. Therefore, it is postulated that for type V collagen-induced aggregation both GPIa/IIa and GPIIIb are essential.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694682

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens.

Authors:  Gavin E Jarvis; Ben T Atkinson; Daniel C Snell; Steve P Watson
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

2.  The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen.

Authors:  A Poole; J M Gibbins; M Turner; M J van Vugt; J G van de Winkel; T Saito; V L Tybulewicz; S P Watson
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function.

Authors:  A Aszódi; A Pfeifer; M Ahmad; M Glauner; X H Zhou; L Ny; K E Andersson; B Kehrel; S Offermanns; R Fässler
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

4.  Thrombospondin modulates melanoma--platelet interactions and melanoma tumour cell growth in vivo.

Authors:  H Boukerche; O Berthier-Vergnes; E Tabone; M Bailly; J F Doré; J L McGregor
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.